Spanish Red Biotech Pipeline

MSD

MK1308A , MK4280A, MK6482, MK4830, Pembrolizumab and Lenvatinib

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Umbrella trial Immune & Targeted Combin Therapies as 1st line treatm in RCC subj w/MK1308A+Lenva or MK4280A+Lenva or MK 6482+Pembro+Lenva vs Pembro+Lenva or as 2nd line & beyond treatm in RCC subj w/MK1308A or MK4280A or MK4830+Pembro or MK6482+Pembro+Len
Phase: 2Phase II in Spain, 1Phase I in Spain